Pooled Analysis of S-1 Trials in Non-Small Cell Lung Cancer According to Histological Type5 O! e# v) [! y7 v+ k+ Q
NOBUYUKI YAMAMOTO1, TAKEHARU YAMANAKA2, YUKITO ICHINOSE3, KAORU KUBOTA4, HIROSHI SAKAI5, AKIHIKO GEMMA6, NAGAHIRO SAIJO7, MASAHIRO FUKUOKA8 and HISANOBU NIITANI9
: n/ A+ @# ~! I4 G3 h, Y+ Author Affiliations o' L+ W% ]( s2 b6 e+ M
0 P6 ^1 f' A4 [1 y9 `" l; \7 }
1Division of Thoracic Oncology, Shizuoka Cancer Center, Shizuoka 411-8777, Japan @9 O2 T1 `$ t1 T* Y" K
2Cancer Biostatistics Laboratory, Institute for Clinical Research, National Kyushu Cancer Center, Fukuoka 811-1395, Japan 1 N# {- E$ P$ ~
3Department of Thoracic Oncology, National Kyushu Cancer Center, Fukuoka 811-1395, Japan & i4 A. O' N6 H8 j
4Division of Thoracic Oncology, National Cancer Center Hospital, Tokyo 104-0045, Japan
4 F# _8 F- I" S: ~5Division of Thoracic Oncology, Saitama Cancer Center, Saitama 362-0806, Japan / z }2 m0 Z+ ~0 {! k$ Y
6Division of Pulmonary Medicine, Infectious Diseases, and Oncology Department of Internal Medicine, Nippon Medical School, Tokyo 113-8603, Japan - K( ^6 S |- h+ n& _4 K
7Kinki University School of Medicine, Osaka 589-8511, Japan ( ^ `: f' [0 L6 L* e1 H* p' ~% S
8Izumi Municipal Hospital, Osaka 594-0071, Japan
( S$ p8 A7 Q$ x0 t7 G9Tokyo Cooperative Oncology Group, Tokyo 105-0013, Japan
: d8 b* f" I* PCorrespondence to: Nobuyuki Yamamoto, Division of Thoracic Oncology, Shizuoka Cancer Center, 1007 Shimonagakubo, Nagaizumi-cho, Sunto-gun, Shizuoka 411-8777, Japan. Tel: +81 559895222, Fax: +81 559895783, e-mail: n.yamamoto@scchr.jp ; t2 Z, B# C8 _/ A: v9 ^9 {
AbstractBackground: The antimetabolic agent S-1 inhibits thymidylate synthase similar to pemetrexed, but through a different mechanism of action. Whether the antitumour activity of S-1 depends on histological type remains unclear. We analysed pooled data from 2 phase II clinical studies of cisplatin and S-1 in patients with previously untreated advanced non-small cell lung cancer. Patients and Methods: We comprised 110 patients with stage IIIB or IV non–small cell lung cancer. Univariate and multivariate analyses were performed to determine the effects of histological type on progression-free survival and response rates. Results: On pooled analysis of the data, according to histological type, median progression-free survival was 3.8 months in patients with squamous cell carcinoma and 4.4 months in those with non-squamous cell carcinoma. Both analyses showed that progression-free survival and response rate did not differ significantly. Conclusion: Unlike molecular targeted agents and pemetrexed, a combination of cisplatin and S-1 may be no difference in response according to histological type.
. j4 s- x" V: _# Q' y& x& j
( t7 y7 _$ }# u+ D- x# B' p |